Baseline Patient Characteristics for Agitation Control Drug Trial in TBI

189 adult patient records from a prospective observational study comparing sodium valproate, levetiracetam, and phenytoin for agitation control after traumatic brain injury. The dataset, authored by Shivani Singh and last updated in June 2026, includes Richmond Agitation-Sedation Scale (RASS) scores measured at baseline and over seven days. It was used to evaluate the percentage of patients achieving agitation-relief and adverse event patterns across the three drug groups.

Use Cases

• Compare drug efficacy for agitation-relief based on reported percentages for sodium valproate (85.7%), levetiracetam (63.5%), and phenytoin.
• Analyze time-to-effect patterns based on the median days to achieve agitation-relief reported for each drug.
• Evaluate drug safety profiles based on the described pattern of adverse events among the three groups.
• Model patient response progression using the day-by-day percentages of patients achieving agitation-relief mentioned in the results.

Strengths

• Contains data from 189 adult patients, providing a substantive cohort for analysis.
• Includes serial Richmond Agitation-Sedation Scale measurements over a seven-day period, enabling longitudinal assessment.
• Directly compares three specific antiepileptic drugs (sodium valproate, levetiracetam, phenytoin) with reported statistical significance (P-values).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 9.5 KB, indicating limited scope and feature depth.

Provenance

Source

figshare

Collection Method

Prospective observational study.

Freshness

Last updated 2026-06-03 17:54:41; freshness should be verified.